Lebrikizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11914 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 41 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | severe nonproliferative diabetic retinopathy | KG + DL |
| 2 | drug-induced osteoporosis | KG + DL |
| 3 | diabetic retinopathy | KG + DL |
| 4 | primary release disorder of platelets | KG + DL |
| 5 | dermatitis | KG + DL |
| 6 | pseudo-von Willebrand disease | KG + DL |
| 7 | Glanzmann thrombasthenia | KG + DL |
| 8 | neonatal dermatomyositis | KG + DL |
| 9 | psoriasis | KG + DL |
| 10 | HER2 positive breast carcinoma | KG + DL |
| 11 | acrodermatitis chronica atrophicans | KG + DL |
| 12 | amyopathic dermatomyositis | KG + DL |
| 13 | acne keloid | KG + DL |
| 14 | diabetic cataract | KG + DL |
| 15 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 16 | hydroa vacciniforme, familial | KG + DL |
| 17 | nuclear senile cataract | KG + DL |
| 18 | cortical cataract | KG + DL |
| 19 | senile cataract | KG + DL |
| 20 | diabetes mellitus type 2 associated cataract | KG + DL |
| 21 | tetanic cataract | KG + DL |
| 22 | mature cataract | KG + DL |
| 23 | immature cataract | KG + DL |
| 24 | craniostenosis cataract | KG + DL |
| 25 | progesterone-receptor positive breast cancer | KG + DL |
| 26 | normal breast-like subtype of breast carcinoma | KG + DL |
| 27 | breast tumor luminal A or B | KG + DL |
| 28 | pityriasis lichenoides | KG + DL |
| 29 | progesterone-receptor negative breast cancer | KG + DL |
| 30 | pancytopenia due to IKZF1 mutations | KG + DL |
| 31 | multifocal choroiditis | KG + DL |
| 32 | thrombocytopenia due to immune destruction | KG + DL |
| 33 | autoimmune thrombocytopenic | KG + DL |
| 34 | hepatic veno-occlusive disease-immunodeficiency syndrome | KG + DL |
| 35 | combined immunodeficiency due to CRAC channel dysfunction | KG + DL |
| 36 | hepatic infarction | KG + DL |
| 37 | absent thumb-short stature-immunodeficiency syndrome | KG + DL |
| 38 | autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis | KG + DL |
| 39 | immuno-osseous dysplasia | KG + DL |
| 40 | peliosis hepatis | KG + DL |
| 41 | facial dysmorphism-immunodeficiency-livedo-short stature syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.